arrow
H

H. Berna Beverloo

erasmus university medical center
H指数:67
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MDS/AML AND AML WITH MYELODYSPLASIA-RELATED GENE MUTATIONS: CLINICAL AND MOLECULAR SIMILARITIES

MDS/AML和AML伴骨髓增生异常相关基因突变: 临床和分子相似性

2026-01-160
OAAI
MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia

MECOM 是通过剂量调控 CEBPA 来抑制髓系分化的急性髓系白血病中的主效抑制因子。

Blood
IF23.1
2025-10-100
PRE
Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B-ALL, or T-ALL

转录谱分析指导将起源不明的急性白血病分类为AML、B-ALL或T-ALL。

2025-08-190
OAAI
A revised prognostic model for patients with acute myeloid leukemia and first relapse

针对急性髓系白血病首次复发的修订型预后模型

2025-05-260
OA
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

Inotuzumab ozogamicin联合化疗治疗小儿B细胞前体CD22急性淋巴细胞白血病: IB期ITCC-059试验的结果

2024-01-045
OAAI
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

Inotuzumab ozogamicin作为复发和难治性急性淋巴细胞白血病患儿的单一药物: II期试验的结果

LEUKEMIA
IF13.4
2022-04-2536
OAAI
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
2022-02-119
OAAI
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial
2020-12-1823
OAAI
ACO2 homozygous missense mutation associated with complicated hereditary spastic paraplegia
2018-04-0122
OAAI
Candidate CSPG4 mutations and induced pluripotent stem cell modeling implicate oligodendrocyte progenitor cell dysfunction in familial schizophrenia
2018-01-0450
OAAI